FindTrial
Sign In

CYP3A activity during nontuberculous mycobacterium infection

CYP3A activity during nontuberculous mycobacterium infection - CYP3A activity during nontuberculous mycobacterium infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000027308
Enrollment
20
Registered
2017-05-15
Start date
2017-05-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nontuberculous Mycobacterial Lung Disease

Interventions

midazolam 1mg

Sponsors

Hamamatsu university school of medicine Second division, depertment of internal medicine
Lead Sponsor
Respiratory meidicine, National hospital organization Tenryu hospital Department of clinical pharmacology and therapeutics, Hamamatsu university school of medicine
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients aged 20 years or older who treat nontuberculous mycobacterium infection using rifampicin and clarithromycin. 2) Patients who do not have drug allergy or idiosyncrasy. 3) Patients who do not have a history of drug dependence, alcohol dependence, etc. 4) Patients who can obtain written consent.

Exclusion criteria

Exclusion criteria: 1) The history of drug hypersensitivity. 2) The presence of severe renal or liver dysfunction. 3) Patients who are unable to continue taking medicine.

Design outcomes

Primary

MeasureTime frame
CYP3A activity—

Secondary

MeasureTime frame
Pharmacokinetics, Safety—

Countries

Japan

Contacts

Public ContactShinpei Kato

Hamamatsu university school of medicine Second division, depertment of internal medicine

skato@hama-med.ac.jp053-435-2263

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026